FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891331723> ?p ?o ?g. }

• W2891331723 endingPage "1901" @default.
• W2891331723 startingPage "1896" @default.
• W2891331723 abstract "Patients with both acute coronary syndromes (ACS) and congestive heart failure are at an increased risk of recurrent cardiovascular (CV) events attributed in part to both excess thrombin generation and impaired fibrinolysis. We hypothesized that patients with the overlap of ACS and CHF would thus derive particular benefit from antithrombotic therapy with rivaroxaban. ATLAS-ACS-2 Thrombolysis in Myocardial Infarction-51 was a double-blind, multicenter, phase 3 clinical trial that randomized patients within 7 days of an ACS event to standard of care plus either rivaroxaban 2.5 mg BID, 5 mg BID, or placebo (n = 15,526). In this post hoc subgroup analysis, subjects with a history of CHF at randomization (n = 1,694) were evaluated. Among subjects with a history of CHF, both rivaroxaban doses reduced the primary composite end point of CV death, myocardial infarction, or stroke (2.5 mg BID vs placebo: hazard ratio [HR] 0.59, 95% confidence interval [CI] (0.42, 0.81), p = 0.001; 5 mg BID vs placebo: HR 0.61, 95% CI (0.44, 0.84), p = 0.002; p interaction = 0.006). Both doses of rivaroxaban reduced CV mortality (rivaroxaban 2.5 mg BID vs placebo: 4.1% vs 9.0%, HR 0.45, 95% CI [0.27, 0.74], p = 0.002; rivaroxaban 5 mg BID vs placebo: 5.8% vs 9.0%, HR 0.62, 95% CI [0.40, 0.96], p = 0.031) as well as all-cause mortality. There was no significant increase in noncoronary artery bypass graft-related Thrombolysis in Myocardial Infarction major bleeding with either dose of rivaroxaban as compared with placebo (rivaroxaban 2.5 mg BID = 0.4% vs rivaroxaban 5 mg BID = 1.1% vs placebo = 0.5%). Rivaroxaban also did not increase either intracranial hemorrhage or fatal bleeding. In conclusion, in ACS subjects with a history of CHF, secondary prevention with rivaroxaban reduced the composite of CV death, myocardial infarction, or stroke without an increase in noncoronary artery bypass graft-related major bleeding. These findings require further prospective evaluation in an adequately powered phase 3 study." @default.
• W2891331723 created "2018-09-27" @default.
• W2891331723 creator A5007026783 @default.
• W2891331723 creator A5010571732 @default.
• W2891331723 creator A5017098029 @default.
• W2891331723 creator A5022267024 @default.
• W2891331723 creator A5034203412 @default.
• W2891331723 creator A5039443786 @default.
• W2891331723 creator A5052994249 @default.
• W2891331723 creator A5059839159 @default.
• W2891331723 creator A5065978967 @default.
• W2891331723 creator A5066403065 @default.
• W2891331723 creator A5068302103 @default.
• W2891331723 date "2018-12-01" @default.
• W2891331723 modified "2023-09-26" @default.
• W2891331723 title "Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial)" @default.
• W2891331723 cites W1604096140 @default.
• W2891331723 cites W1722983215 @default.
• W2891331723 cites W1965221121 @default.
• W2891331723 cites W1969750108 @default.
• W2891331723 cites W2017969964 @default.
• W2891331723 cites W2020336064 @default.
• W2891331723 cites W2023215593 @default.
• W2891331723 cites W2032105970 @default.
• W2891331723 cites W2042888704 @default.
• W2891331723 cites W2055698835 @default.
• W2891331723 cites W2065276135 @default.
• W2891331723 cites W2082048621 @default.
• W2891331723 cites W2099261067 @default.
• W2891331723 cites W2102355502 @default.
• W2891331723 cites W2116668909 @default.
• W2891331723 cites W2117677020 @default.
• W2891331723 cites W2120865130 @default.
• W2891331723 cites W2123262447 @default.
• W2891331723 cites W2138704793 @default.
• W2891331723 cites W2145814747 @default.
• W2891331723 cites W2158910198 @default.
• W2891331723 cites W2339002542 @default.
• W2891331723 cites W2735153003 @default.
• W2891331723 doi "https://doi.org/10.1016/j.amjcard.2018.08.034" @default.
• W2891331723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30340765" @default.
• W2891331723 hasPublicationYear "2018" @default.
• W2891331723 type Work @default.
• W2891331723 sameAs 2891331723 @default.
• W2891331723 citedByCount "15" @default.
• W2891331723 countsByYear W28913317232019 @default.
• W2891331723 countsByYear W28913317232020 @default.
• W2891331723 countsByYear W28913317232021 @default.
• W2891331723 countsByYear W28913317232022 @default.
• W2891331723 crossrefType "journal-article" @default.
• W2891331723 hasAuthorship W2891331723A5007026783 @default.
• W2891331723 hasAuthorship W2891331723A5010571732 @default.
• W2891331723 hasAuthorship W2891331723A5017098029 @default.
• W2891331723 hasAuthorship W2891331723A5022267024 @default.
• W2891331723 hasAuthorship W2891331723A5034203412 @default.
• W2891331723 hasAuthorship W2891331723A5039443786 @default.
• W2891331723 hasAuthorship W2891331723A5052994249 @default.
• W2891331723 hasAuthorship W2891331723A5059839159 @default.
• W2891331723 hasAuthorship W2891331723A5065978967 @default.
• W2891331723 hasAuthorship W2891331723A5066403065 @default.
• W2891331723 hasAuthorship W2891331723A5068302103 @default.
• W2891331723 hasBestOaLocation W28913317231 @default.
• W2891331723 hasConcept C126322002 @default.
• W2891331723 hasConcept C142724271 @default.
• W2891331723 hasConcept C164705383 @default.
• W2891331723 hasConcept C168563851 @default.
• W2891331723 hasConcept C203092338 @default.
• W2891331723 hasConcept C204787440 @default.
• W2891331723 hasConcept C207103383 @default.
• W2891331723 hasConcept C27081682 @default.
• W2891331723 hasConcept C2776301958 @default.
• W2891331723 hasConcept C2777698277 @default.
• W2891331723 hasConcept C2777995511 @default.
• W2891331723 hasConcept C2778198053 @default.
• W2891331723 hasConcept C2778213512 @default.
• W2891331723 hasConcept C2778661090 @default.
• W2891331723 hasConcept C2779161974 @default.
• W2891331723 hasConcept C2779581417 @default.
• W2891331723 hasConcept C44249647 @default.
• W2891331723 hasConcept C500558357 @default.
• W2891331723 hasConcept C71924100 @default.
• W2891331723 hasConceptScore W2891331723C126322002 @default.
• W2891331723 hasConceptScore W2891331723C142724271 @default.
• W2891331723 hasConceptScore W2891331723C164705383 @default.
• W2891331723 hasConceptScore W2891331723C168563851 @default.
• W2891331723 hasConceptScore W2891331723C203092338 @default.
• W2891331723 hasConceptScore W2891331723C204787440 @default.
• W2891331723 hasConceptScore W2891331723C207103383 @default.
• W2891331723 hasConceptScore W2891331723C27081682 @default.
• W2891331723 hasConceptScore W2891331723C2776301958 @default.
• W2891331723 hasConceptScore W2891331723C2777698277 @default.
• W2891331723 hasConceptScore W2891331723C2777995511 @default.
• W2891331723 hasConceptScore W2891331723C2778198053 @default.
• W2891331723 hasConceptScore W2891331723C2778213512 @default.
• W2891331723 hasConceptScore W2891331723C2778661090 @default.
• W2891331723 hasConceptScore W2891331723C2779161974 @default.
• W2891331723 hasConceptScore W2891331723C2779581417 @default.
• W2891331723 hasConceptScore W2891331723C44249647 @default.

• next